Open AccessCytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience
Author(s) -
Andrew P. Schaefer,
Ying Huang,
Adam S Kittai,
Joseph Maakaron,
Caner Saygin,
Jonathan E. Brammer,
Sam Penza,
Ayman Saad,
Samantha Jaglowski,
Basem M. William
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s321202
Subject(s) - medicine , cytopenia , cytokine release syndrome , follicular lymphoma , neutropenia , diffuse large b cell lymphoma , leukopenia , filgrastim , anemia , chimeric antigen receptor , lymphoma , oncology , immunology , autoimmune hemolytic anemia , gastroenterology , chemotherapy , immunotherapy , bone marrow , cancer
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Treatment with CD19 chimeric antigen receptor (CAR-T) cells, tisagenlecleucel and axicabtagene ciloleucel, has been associated with improved outcomes. Cytopenias were observed in clinical trials with both products; however, little is known regarding the patterns and outcomes of these cytopenias.